A Study of LY3493269 in Participants With Type 2 Diabetes
A Study of LY3493269 in Participants With Type 2 Diabetes
The main purpose of this study is to determine the side effects related to LY3493269 in
 participants with type 2 diabetes. Blood tests will be performed to check concentrations of
 LY3493269 in the bloodstream. Each enrolled participant will receive LY3493269, dulaglutide,
 or placebo. The study will last up to approximately 16 weeks for each participant and may
 include up to 11 visits.
Inclusion Criteria:

 -  Are male or female not of childbearing potential

 -  Have a body mass index of 23 to 50 kilograms per square meter (kg/m²), inclusive, at
 screening

 -  Have had a stable body weight (<5% body weight change) for the 3 months prior to
 screening

 -  Have not modified their diet or adopted any nutritional lifestyle modification in the
 3 months prior to screening

 -  Have type 2 diabetes mellitus (T2DM) controlled with diet and exercise alone or are on
 a stable dose of metformin for at least 3 months before screening. Patients with
 comorbid conditions commonly associated with diabetes (for example, hypertension,
 hypercholesterolemia, hypothyroidism) may be eligible for inclusion if conditions are
 assessed by the investigator to be well controlled and stable for at least 3 months
 prior to screening

 -  Have an HbA1c of at least 7.0% and no more than 10.5% at screening

 -  Have clinical laboratory test results within the normal range for the population or
 investigative site, or with abnormalities deemed not clinically significant by the
 investigator

 Exclusion Criteria:

 -  Have type 1 diabetes mellitus or latent autoimmune diabetes in adults

 -  Have uncontrolled diabetes, defined as an episode of ketoacidosis or hyperosmolar
 state requiring hospitalization in the 6 months prior to screening

 -  Have a history of proliferative diabetic retinopathy, diabetic maculopathy, or severe
 nonproliferative diabetic retinopathy that requires acute treatment

 -  Have had more than 1 episode of severe hypoglycemia, as defined by the American
 Diabetes Association criteria, within 6 months before screening or has a history of
 hypoglycemia unawareness or poor recognition of hypoglycemic symptoms.

 -  Have a definitive diagnosis of autonomic neuropathy as evidenced by urinary retention,
 resting tachycardia, orthostatic hypotension, or diabetic diarrhea

 -  Have a history of acute or chronic pancreatitis

 -  Have a self or family history (first-degree relative) of multiple endocrine neoplasia
 type 2A or type 2B, thyroid C-cell hyperplasia, or medullary thyroid carcinoma

 -  Have calcitonin levels of 20 picograms per millilitre (pg/mL) or more at screening